Apimeds acquires Apitox rights from FreeT: Korean clinic market, 25% US royalty

Apimeds Pharmaceuticals US, Inc.

On Aug 19, 2026, Apimeds entered an Assignment Agreement with FreeT Inc. (successor to CNP Roen/Inscobee).
Assigned rights include 100% of Apitox Korean medicine-clinic market rights and 25% royalty on US Apitox economic proceeds.
Also granted 25% revenue participation on net proceeds from overseas rights deals plus quarterly clinical and commercialization updates.
Company assumes no pre-effective-date liabilities; rights exclude global rights not held by FreeT and underlying Apitox IP.
FreeT will support continued development and expansion and pursue future grants of non-US Apitox territories to Apimeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.